DE69931055D1 - Verwendung von cyclooxygenase-2-inhibitoren zur behandlung von entzündungserkrankungen von kopf und nacken - Google Patents

Verwendung von cyclooxygenase-2-inhibitoren zur behandlung von entzündungserkrankungen von kopf und nacken

Info

Publication number
DE69931055D1
DE69931055D1 DE69931055T DE69931055T DE69931055D1 DE 69931055 D1 DE69931055 D1 DE 69931055D1 DE 69931055 T DE69931055 T DE 69931055T DE 69931055 T DE69931055 T DE 69931055T DE 69931055 D1 DE69931055 D1 DE 69931055D1
Authority
DE
Germany
Prior art keywords
cyclooxygenase
neck
head
inhibitor
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69931055T
Other languages
English (en)
Other versions
DE69931055T2 (de
Inventor
J Dannenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell Research Foundation Inc
Original Assignee
Cornell Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Research Foundation Inc filed Critical Cornell Research Foundation Inc
Publication of DE69931055D1 publication Critical patent/DE69931055D1/de
Application granted granted Critical
Publication of DE69931055T2 publication Critical patent/DE69931055T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69931055T 1998-09-08 1999-07-29 Verwendung von cyclooxygenase-2-inhibitoren zur behandlung von entzündungserkrankungen von kopf und nacken Expired - Lifetime DE69931055T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9934398P 1998-09-08 1998-09-08
US99343P 1998-09-08
PCT/US1999/016685 WO2000013685A1 (en) 1998-09-08 1999-07-29 Treating inflammatory diseases of the head and neck with cyclooxygenase-2 inhibitors

Publications (2)

Publication Number Publication Date
DE69931055D1 true DE69931055D1 (de) 2006-06-01
DE69931055T2 DE69931055T2 (de) 2006-12-07

Family

ID=22274554

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69931055T Expired - Lifetime DE69931055T2 (de) 1998-09-08 1999-07-29 Verwendung von cyclooxygenase-2-inhibitoren zur behandlung von entzündungserkrankungen von kopf und nacken

Country Status (7)

Country Link
US (1) US6486203B1 (de)
EP (1) EP1109553B1 (de)
AT (1) ATE324105T1 (de)
CA (1) CA2339049C (de)
DE (1) DE69931055T2 (de)
ES (1) ES2258337T3 (de)
WO (1) WO2000013685A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887901B1 (en) 1993-06-15 2005-05-03 Brigham & Women's Hospital, Inc. Lipoxin compounds and their use in treating cell proliferative disorders
US6048897A (en) 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
US6716883B1 (en) * 1998-12-24 2004-04-06 1333366 Ontario Inc. Composition useful to treat periodontal disease
PE20010540A1 (es) * 1999-07-30 2001-05-15 Procter & Gamble Composicion de fitoalexinas estilbenicas util para la profilaxis y tratamiento de sintomas asociados con el resfriado y enfermedades similares a la influenza
EP1268393A2 (de) 2000-03-20 2003-01-02 Trustees Of Boston University Lipoxinanaloge und verfahren zur behandlung von periodontalen erkrankungen
AU2001266895A1 (en) * 2000-06-13 2001-12-24 Wyeth Phytonutrient formula for the relief of chronic pain resulting from inflammation
US6878751B1 (en) * 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
DE60236273D1 (de) 2001-05-03 2010-06-17 Cornell Res Foundation Inc Behandlung von krankheiten, die durch hpv verursacht werden
US6979470B2 (en) * 2001-07-17 2005-12-27 Metaproteomics, Llc Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
WO2003039533A1 (en) 2001-11-06 2003-05-15 The Brigham And Women's Hospital, Inc. Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
EP1458373A1 (de) 2001-12-18 2004-09-22 The Brigham and Women's Hospital Verwendung von lipoxin analoga zur steigerung der zellverteidigung gegen durch gramnegative bakterien hervorgerufene infektionen
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
AU2003251587A1 (en) 2002-08-22 2004-03-11 Cornell Research Foundation, Inc. Multifunctional cox-2 inhibitors
US7582674B2 (en) * 2003-05-27 2009-09-01 Dsm Ip Assets B.V. Nutraceutical compositions and use thereof
JP2007530417A (ja) 2003-07-01 2007-11-01 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 細胞及び生物の寿命及びストレス応答を操作するための組成物
DE10352369A1 (de) * 2003-11-10 2005-06-09 Beiersdorf Ag Verwendung von Licocalchon A oder eines Licocalchon A enthaltenden Extraktes aus Radix Glycyrrhizae inflatae gegen postinflammatorische Hyperpigmentierung
DE10352368A1 (de) * 2003-11-10 2005-06-09 Beiersdorf Ag Verwendung von Licochalkon A zur Behandlung von Insektenstichen
DE10352367A1 (de) * 2003-11-10 2005-06-09 Beiersdorf Ag Verwendung von Licochalkon A gegen Rosacea
DE10356869A1 (de) 2003-12-03 2005-07-07 Beiersdorf Ag Tensidhaltige Zubereitung mit Licochalcon A
JP2007527418A (ja) 2003-12-29 2007-09-27 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 肥満及びインシュリン耐性障害を治療又は防止するための組成物
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
US20080044455A1 (en) * 2006-08-21 2008-02-21 Chaim Welczer Tonsillitus Treatment
US9700525B2 (en) * 2008-08-20 2017-07-11 Board Of Supervisors Of Louisiana State University And Agricultural & Mechanical College Continuous local slow-release of therapeutics for head and neck problems and upper aerodigestive disorders
CN104367775A (zh) * 2014-12-08 2015-02-25 田丽华 一种用于治疗扁桃体炎的中药
EP3481409A4 (de) * 2016-07-11 2020-03-18 The State of Isreal, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) Behandlung von follikulärer tonsillitis mit pflanzenextrakten mit carnosinsäure
US11103465B2 (en) 2017-11-22 2021-08-31 Ted's Brain Science, Inc. Trans-resveratrol topical medication for the treatment of pain and method of manufacture thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870210A (en) 1987-12-18 1989-09-26 American Home Products Corporation Aminoguanidine derivative as anti-inflammatory agents
JP3207912B2 (ja) * 1991-03-15 2001-09-10 カネボウ株式会社 コラゲナーゼ活性阻害剤
US5710181A (en) 1991-12-16 1998-01-20 Washington University Inhibition of nitric oxide formation in inflammatory bowel disease
US6048850A (en) 1992-09-22 2000-04-11 Young; Donald A. Method of inhibiting prostaglandin synthesis in a human host
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
GB9602877D0 (en) * 1996-02-13 1996-04-10 Merck Frosst Canada Inc 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
GB2317339A (en) * 1996-08-01 1998-03-25 Procter & Gamble Dentifrice composition containing a curcuminoid

Also Published As

Publication number Publication date
ATE324105T1 (de) 2006-05-15
ES2258337T3 (es) 2006-08-16
CA2339049A1 (en) 2000-03-16
WO2000013685A1 (en) 2000-03-16
EP1109553A4 (de) 2003-12-10
CA2339049C (en) 2010-02-23
EP1109553A1 (de) 2001-06-27
US6486203B1 (en) 2002-11-26
EP1109553B1 (de) 2006-04-26
DE69931055T2 (de) 2006-12-07

Similar Documents

Publication Publication Date Title
DE69931055D1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung von entzündungserkrankungen von kopf und nacken
DE69616375T2 (de) Nicht-allosterische GABA A Agonisten zur Behandlung von Schlafstörungen
DE60115842D1 (de) Ventilanordnung
MX9803753A (es) Acidos alfa-iminohidroxamicos y -carboxilicos n-sustituidos ciclicos y heterociclicos.
DE69230046D1 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
DE60128540D1 (de) Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen
EP1390491A4 (de) Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren
DE69613840T2 (de) Orale dosierungsform und verfahren zur behandlung von schmerzzuständen in dermundhöhle
HUP0401867A2 (hu) A valproinsav-amid és a 2-valproénsav-amid származékainak használata a fájdalommal és a fejfájással járó betegségek kezelésére vagy megelőzésére
NO20011440L (no) mGluR5-antagonister for behandling av smerte og angst
CY1106155T1 (el) Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους
ATE447403T1 (de) Cannabinoiden zur behandlung von während des schlafens auftretenden atmungsstörungen
ATE177646T1 (de) Protein präparate zur verhütung und behandlung van periodontitis und sonstigen bakteriellen erkrankungen der mundhöhle
DE69832176D1 (de) Arzneimittel gegen diabetes-komplikationen
DK1343472T3 (da) Thixotropisk næsespray
DE69932922D1 (de) Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen
BR0308795A (pt) Amidas do ácido sulfamico
CO5130011A1 (es) Nuevos usos farmaceuticos para inhibidores nos
NO20045343L (no) Ny kombinasjon for behandling av luftveisforstyrrelser
EE9700350A (et) COMT-inhibiitorite uus kasutamine ja diabeetiliste vaskulaarsete häirete ärahoidmise meetod
KR930702016A (ko) 골다공증 치료제
NO960866L (no) Fremgangsmåte til behandling av leversykdom og lignende indikasjoner med vasodilaterende midler
UA38085A (uk) Спосіб лікування ранніх гестозів
BG105322A (en) New pharmaceutical use for nos inhibitors
UA39758A (uk) Спосіб лікування хронічного уретропростатиту хламідійно-уреаплазмової етіології

Legal Events

Date Code Title Description
8364 No opposition during term of opposition